- Home
- CYRX vs SLDB Comparison
CYRX vs SLDB Comparison
Compare CYRX & SLDB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYRX
- SLDB
- Stock Information
- Founded
- CYRX 1999
- SLDB 2013
- Country
- CYRX United States
- SLDB United States
- Employees
- CYRX N/A
- SLDB N/A
- Industry
- CYRX Biotechnology: Pharmaceutical Preparations
- SLDB Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CYRX Health Care
- SLDB Health Care
- Exchange
- CYRX Nasdaq
- SLDB Nasdaq
- Market Cap
- CYRX 277.5M
- SLDB 234.8M
- IPO Year
- CYRX N/A
- SLDB 2018
- Fundamental
- Price
- CYRX $5.40
- SLDB $3.54
- Analyst Decision
- CYRX Strong Buy
- SLDB Strong Buy
- Analyst Count
- CYRX 8
- SLDB 10
- Target Price
- CYRX $10.75
- SLDB $14.90
- AVG Volume (30 Days)
- CYRX 457.1K
- SLDB 1.9M
- Earning Date
- CYRX 05-07-2025
- SLDB 05-15-2025
- Dividend Yield
- CYRX N/A
- SLDB N/A
- EPS Growth
- CYRX N/A
- SLDB N/A
- EPS
- CYRX N/A
- SLDB N/A
- Revenue
- CYRX $232,134,000.00
- SLDB N/A
- Revenue This Year
- CYRX N/A
- SLDB N/A
- Revenue Next Year
- CYRX $9.41
- SLDB N/A
- P/E Ratio
- CYRX N/A
- SLDB N/A
- Revenue Growth
- CYRX 11.75
- SLDB N/A
- 52 Week Low
- CYRX $4.58
- SLDB $2.41
- 52 Week High
- CYRX $11.64
- SLDB $10.37
- Technical
- Relative Strength Index (RSI)
- CYRX 37.87
- SLDB 57.65
- Support Level
- CYRX $5.91
- SLDB $2.68
- Resistance Level
- CYRX $6.16
- SLDB $3.32
- Average True Range (ATR)
- CYRX 0.41
- SLDB 0.28
- MACD
- CYRX -0.12
- SLDB 0.10
- Stochastic Oscillator
- CYRX 0.50
- SLDB 87.94
About CYRX CryoPort Inc.
CryoPort Inc is a leader serving the life sciences industry as a provider of integrated temperature-controlled supply chain solutions supporting the life sciences in the biopharma/pharma, animal health, and reproductive medicine markets. It operates in two reportable segments: Life Sciences Services and Life Sciences Products. Geographically the company operates in the Americas, Europe, the Middle East and Africa (EMEA), and Asia Pacific (APAC), generating a majority of its revenue from the Americas.
About SLDB Solid Biosciences Inc.
Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company's singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.